FDA Fast Track Designation: A Double Edged Sword for Erasca's Pancreatic Cancer Hope The recent FDA grant of Fast Track designation to Erasca's ERAS 0015, an oral pan RAS molecular glue, has sent shockwaves through the biotech community.
This regulatory shortcut is a significant coup for Erasca, but it also highlights the high stakes and substantial costs associated with developing treatments for pancreatic cancer.
The science behind ERAS 0015 is promising, particularly in patients with second line or later KRAS G12X pancreatic cancer who received the treatment, with a 57% response rate.